Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Bath & Body Works Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.37 (market cap $863.95M), while Bath & Body Works Inc trades at $19.05 (market cap $3.89B). The key difference: Bath & Body Works Inc is far larger — about 4.5× Amphastar Pharmaceuticals Inc's market cap, and Bath & Body Works Inc pays a 4.14% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BBWI | |
|---|---|---|
Market Cap | $863.95M | $3.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $31.87 |
52-Week Low | $16.87 | $14.85 |
Enterprise Value | $1.26B | $7.79B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
BBWI trades at $20.36, up 1.09% daily, with a bearish technical signal but strong fundamentals including a low P/E of 5.78 and net income margin of 10.03%. Recent earnings show mixed beats, while cash flow trends improved in 2026 forecasts. The company expands globally via Ulta Beauty partnerships and Brazil entry, supporting growth narratives amid revenue declines from $7.9B in 2022 to $7.3B in 2025.
Outlook balances deep value with execution risks; analyst consensus price target of $22.11 implies upside, but high debt and revenue pressures require monitoring turnaround initiatives. Opportunities lie in margin strength and expansion, while risks include competitive retail headwinds and liability management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
